Altered hypothalamic cholinergic responses in patients with nonulcer dyspepsia: A study of pyridostigmine-stimulated growth hormone release

Typeset version

 

TY  - JOUR
  - Dinan, TG,Scott, LV,Brady, D,McNamara, D,Keeling, PWN
  - 2002
  - February
  - American Journal of Gastroenterology
  - Altered hypothalamic cholinergic responses in patients with nonulcer dyspepsia: A study of pyridostigmine-stimulated growth hormone release
  - Validated
  - ()
  - DEPRESSION SECRETION CISAPRIDE MOTILITY
  - 97
  - 1937
  - 1940
  - OBJECTIVE: Acetylcholine plays a central and peripheral role in regulating gastric motility. In the hypothalamus, it is a key neuroendocrine modulator; acting through somatostatin, it brings about the release of growth hormone (GH). We measured hypothalamic cholinergic receptor sensitivity in patients with nonulcer dyspepsia (NUD) by examining GH release in response to cholinergic challenge. METHODS: Forty patients with NUD and 40 healthy comparison subjects were administered pyridostigmine (the acetylcholinesterase inhibitor, 120 mg), and GH release over a 3-h period was monitored. RESULTS: Calculating response as the maximum GH relative to baseline (delta GH), the mean +/-SEM response in the patients was 11.9 +/- 1.9 U/L and in the healthy subjects 6.7 +/- 0.7 mU/L (t = 2.1, df = 78, p = 0.03). Helicobacter pylori status had no appreciable impact on GH response with H. pylori-positive patients having a mean response of 10.5 +/- 2.1 mU/L and negative patients a mean response of 13.2 +/- 3.4 mU/L. Overall, patients with NUD release more GH in response to pyridostigmine challenge than healthy subjects. CONCLUSIONS: Patients with NUD may have a pathophysiological disturbance involving central cholinergic systems.
  - PII S0002-9270(02)04260-0
DA  - 2002/02
ER  - 
@article{V43338088,
   = {Dinan,  TG and Scott,  LV and Brady,  D and McNamara,  D and Keeling,  PWN },
   = {2002},
   = {February},
   = {American Journal of Gastroenterology},
   = {Altered hypothalamic cholinergic responses in patients with nonulcer dyspepsia: A study of pyridostigmine-stimulated growth hormone release},
   = {Validated},
   = {()},
   = {DEPRESSION SECRETION CISAPRIDE MOTILITY},
   = {97},
  pages = {1937--1940},
   = {{OBJECTIVE: Acetylcholine plays a central and peripheral role in regulating gastric motility. In the hypothalamus, it is a key neuroendocrine modulator; acting through somatostatin, it brings about the release of growth hormone (GH). We measured hypothalamic cholinergic receptor sensitivity in patients with nonulcer dyspepsia (NUD) by examining GH release in response to cholinergic challenge. METHODS: Forty patients with NUD and 40 healthy comparison subjects were administered pyridostigmine (the acetylcholinesterase inhibitor, 120 mg), and GH release over a 3-h period was monitored. RESULTS: Calculating response as the maximum GH relative to baseline (delta GH), the mean +/-SEM response in the patients was 11.9 +/- 1.9 U/L and in the healthy subjects 6.7 +/- 0.7 mU/L (t = 2.1, df = 78, p = 0.03). Helicobacter pylori status had no appreciable impact on GH response with H. pylori-positive patients having a mean response of 10.5 +/- 2.1 mU/L and negative patients a mean response of 13.2 +/- 3.4 mU/L. Overall, patients with NUD release more GH in response to pyridostigmine challenge than healthy subjects. CONCLUSIONS: Patients with NUD may have a pathophysiological disturbance involving central cholinergic systems.}},
   = {PII S0002-9270(02)04260-0},
  source = {IRIS}
}
AUTHORSDinan, TG,Scott, LV,Brady, D,McNamara, D,Keeling, PWN
YEAR2002
MONTHFebruary
JOURNAL_CODEAmerican Journal of Gastroenterology
TITLEAltered hypothalamic cholinergic responses in patients with nonulcer dyspepsia: A study of pyridostigmine-stimulated growth hormone release
STATUSValidated
TIMES_CITED()
SEARCH_KEYWORDDEPRESSION SECRETION CISAPRIDE MOTILITY
VOLUME97
ISSUE
START_PAGE1937
END_PAGE1940
ABSTRACTOBJECTIVE: Acetylcholine plays a central and peripheral role in regulating gastric motility. In the hypothalamus, it is a key neuroendocrine modulator; acting through somatostatin, it brings about the release of growth hormone (GH). We measured hypothalamic cholinergic receptor sensitivity in patients with nonulcer dyspepsia (NUD) by examining GH release in response to cholinergic challenge. METHODS: Forty patients with NUD and 40 healthy comparison subjects were administered pyridostigmine (the acetylcholinesterase inhibitor, 120 mg), and GH release over a 3-h period was monitored. RESULTS: Calculating response as the maximum GH relative to baseline (delta GH), the mean +/-SEM response in the patients was 11.9 +/- 1.9 U/L and in the healthy subjects 6.7 +/- 0.7 mU/L (t = 2.1, df = 78, p = 0.03). Helicobacter pylori status had no appreciable impact on GH response with H. pylori-positive patients having a mean response of 10.5 +/- 2.1 mU/L and negative patients a mean response of 13.2 +/- 3.4 mU/L. Overall, patients with NUD release more GH in response to pyridostigmine challenge than healthy subjects. CONCLUSIONS: Patients with NUD may have a pathophysiological disturbance involving central cholinergic systems.
PUBLISHER_LOCATION
ISBN_ISSN
EDITION
URL
DOI_LINKPII S0002-9270(02)04260-0
FUNDING_BODY
GRANT_DETAILS